


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (Cancelled)

Claim 12 (New): A compound of formula I,



wherein

- R^1 and R^2 are, independently of one another, hydrogen, C_{1-6} alkyl, OR^7 , NR^7R^8 , CN, acyl, CO_2R^9 , $CONR^7R^8$ or $CSNR^7R^8$,
- R^3 is a saturated or unsaturated C_{1-5} alkylene radical, which is optionally substituted in 1 to 4 places with OR^7 , $NR^{11}R^{12}$ or C_{1-4} alkyl and which are optionally bridged with a methano, ethano or propano group,
- R^4 is C_{1-4} alkyl, substituted with $NR^{14}R^{15}$,
- R^4 and R^5 optionally together with 2 adjacent carbon atoms form a C_3 - C_4 alkylene moiety optionally substituted in one or two places with $NR^{14}R^{15}$,
- R^5 and R^6 are, independently of one another, Hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,
- R^7 , R^{18} and R^{19} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,
- R^8 , R^{11} and R^{12} are, independently of one another, Hydrogen, C_{1-6} alkyl, C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl, COR^{10} , CO_2R^{10} , $CONR^{18}R^{19}$ or $CSNR^{18}R^{19}$,

R^9, R^{10}
 and R^{20} are, independently of one another, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,
 R^{14} and R^{15} are, independently of one another, Hydrogen, CO_2R^{20} or C_{1-6} alkyl, which optionally is substituted with halogen, hydroxy, C_{1-4} alkoxy, nitro, amino, C_{1-6} alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C_{3-7} cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C_{6-10} aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, CF_3 , NO_2 , NH_2 , $N(C_{1-4} \text{ alkyl})_2$ or carboxyl, or
 n is 0, 1 or 2,
 or a tautomeric or isomeric form or a salt of a compound of formula I.


Claim 13 (New): A compound according to claim 12, in which R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propano group.

Claim 14 (New): A compound according to claim 12, in which R^1 and R^2 is hydrogen.

Claim 15 (New): A pharmaceutical composition comprising an effective amount of a compound according to claims 12, and a pharmaceutically acceptable vehicle or adjuvant.


Claim 16 (New): A process for the preparation of a pharmaceutical composition comprising combining an effective amount of at least one compound according to claim 12, and at least one solid, liquid or semi-liquid excipient or auxiliary and, optionally, one or more other active compounds.

Claim 17 (New): A process for preparing a compound according to claim 12, comprising reacting a compound of formula (IIa) or (IIb) or a salt thereof



IIa

wherein



IIb

R^3 to R^6 are as defined in claim 1,


R is methyl or ethyl, and

X is O or S,

with ammonia, a primary or secondary amine, hydroxylamine, or hydrazine, and followed by optionally separating isomers or forming a salt.

Claim 18 (New): A method for inhibiting neuronal NDS, comprising administering an effective amount of a compound according to claim 12 or a composition containing said compound to a patient in need thereof.

Claim 19 (New): A compound of formula I,



(I)

wherein

R^1 and R^2 are, each independently, hydrogen or C_{1-6} alkyl,

R^3 is a saturated or unsaturated C_{1-5} alkylene radical, which is optionally substituted in 1 to 4 places with OR^7 , $NR^{11}R^{12}$ or C_{1-4} alkyl and which are optionally bridged with a methano, ethano or propano group,

R^4 is C_{1-4} alkyl, substituted with $NR^{14}R^{15}$,

R^4 and R^5 optionally together with 2 adjacent carbon atoms form a C_3 - C_4 alkylene moiety optionally substituted in one or two places with

$\text{NR}^{14}\text{R}^{15}$,
 R^5 and R^6 are, independently of one another, Hydrogen, halogen, OR^7 , C_{1-4} alkyl, CF_3 , or OCF_3 ,
 R^7 , R^{18}
and R^{19} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,
 R^8 , R^{11}
and R^{12} are, independently of one another, Hydrogen, C_{1-6} alkyl, C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl, COR^{10} , CO_2R^{10} , $\text{CONR}^{18}\text{R}^{19}$ or $\text{CSNR}^{18}\text{R}^{19}$,
 R^9 , R^{10}
and R^{20} are, independently of one another, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,
 R^{14} and R^{15} are, independently of one another, Hydrogen, CO_2R^{20} or C_{1-6} alkyl, which optionally is substituted with halogen, hydroxy, C_{1-4} alkoxy, nitro, amino, C_{1-6} alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C_{3-7} cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C_{6-10} aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, CF_3 , NO_2 , NH_2 , $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$ or carboxyl, or
n is 0, 1 or 2,
or a tautomeric or isomeric form or a salt of a compound of formula I.

Claim 20 (New): A compound according to claim 19, wherein R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propane group.

Claim 21 (New): A method for treating amyotrophic lateral sclerosis, comprising administering an effective amount of a compound according to claim 12 or a composition containing said compound to a patient in need thereof.